Clinical Trial Update: 99mTc Labelled Affibody SPECT/CT Imaging for Breast Cancer HER2 Characterization [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated a 99mTc-labeled Affibody imaging agent for HER2 characterization in breast cancer using SPECT/CT. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 99mTc-labeled Affibody imaging agent for HER2

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Breast Cancer | EARLY_Phase 1 | Status: COMPLETED